• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Fulgent Genetics Inc.

    5/13/25 4:30:21 PM ET
    $FLGT
    Medical Specialities
    Health Care
    Get the next $FLGT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    FULGENT GENETICS INC

    (Name of Issuer)


    COMMON-STOCK

    (Title of Class of Securities)


    359664109

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    359664109


    1Names of Reporting Persons

    Barclays PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,338,024.00
    6Shared Voting Power

    427.00
    7Sole Dispositive Power

    2,338,024.00
    8Shared Dispositive Power

    427.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,338,451.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.57 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    FULGENT GENETICS INC
    (b)Address of issuer's principal executive offices:

    4399 Santa Anita Avenue
    Item 2. 
    (a)Name of person filing:

    Barclays PLC
    (b)Address or principal business office or, if none, residence:

    1 Churchill Place, London - E14 5HP
    (c)Citizenship:

    X0
    (d)Title of class of securities:

    COMMON-STOCK
    (e)CUSIP No.:

    359664109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2338451
    (b)Percent of class:

    7.57  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    2338024

     (ii) Shared power to vote or to direct the vote:

    427

     (iii) Sole power to dispose or to direct the disposition of:

    2338024

     (iv) Shared power to dispose or to direct the disposition of:

    427

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Barclays PLC
     
    Signature:Ramya Rao
    Name/Title:Director
    Date:05/13/2025
    Get the next $FLGT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLGT

    DatePrice TargetRatingAnalyst
    12/7/2023$35.00Neutral
    UBS
    12/8/2022$65.00 → $40.00Overweight → Neutral
    Piper Sandler
    11/18/2022$45.00Outperform
    Raymond James
    8/25/2022$65.00Outperform
    Credit Suisse
    2/4/2022$80.00Overweight
    Piper Sandler
    1/25/2022$141.00 → $125.00Outperform
    Oppenheimer
    8/10/2021$55.00 → $65.00Underperform
    Credit Suisse
    8/5/2021$55.00Underperform
    Credit Suisse
    More analyst ratings

    $FLGT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Fulgent Genetics with a new price target

      UBS initiated coverage of Fulgent Genetics with a rating of Neutral and set a new price target of $35.00

      12/7/23 6:19:41 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Fulgent Genetics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Fulgent Genetics from Overweight to Neutral and set a new price target of $40.00 from $65.00 previously

      12/8/22 7:45:09 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Raymond James initiated coverage on Fulgent Genetics with a new price target

      Raymond James initiated coverage of Fulgent Genetics with a rating of Outperform and set a new price target of $45.00

      11/18/22 7:49:05 AM ET
      $FLGT
      Medical Specialities
      Health Care